Lifespan extension therapy: Rivoglitazone, an anti-hyperglycemic drug,  may increase life span via up-regulation of its target gene BubR1, 19/October/2017, 1.21 am

Natural product therapy for pulmonary arterial hypertension: A therapeutic mix encompassing Curcumin and Quercetin, isolated from Turmeric and Elder berries, respectively, inhibits the development of pulmonary arterial hypertension via down regulation of  Notch3 and its target gene Hes-5, 19/October/2017, 1.00 am
October 18, 2017
Natural product-based therapy for ageing-associated diseases: A therapeutic mix encompassing Lutein, Antacin C & Hesperidin (LAH), isolated from Kale, Antrodia cinnamomea, and Oranges, respectively, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 19/October/2017, 1.49 am
October 18, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:Lifespan extension therapy: Rivoglitazone, an anti-hyperglycemic drug,  may increase life span via up-regulation of its target gene BubR1


What is known? 

Rivoglitazone has been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Rivoglitazoneby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing Rivoglitazone may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Rivoglitazone or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Rivoglitazone increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: Rivoglitazone, an anti-hyperglycemic drug,  may increase life span via up-regulation of its target gene BubR1, 19/October/2017, 1.21 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.